SMARCA4 Screening for Early SCCOHT Characterization and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective biological information and screening methods for Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), a rare and aggressive form of ovarian cancer that often goes undiagnosed at advanced stages and is resistant to chemotherapy, with a high mortality rate due to limited understanding of its genetic drivers.
Innovation Solution
The method involves screening for inactivation alterations in the SWI/SNF complex, particularly in the SMARCA4 gene, to identify SCCOHT or predisposition, and administering therapeutic treatments such as gene therapy, protein replacement, or protein mimetics to address the cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ovarian cancer screening and diagnostic methods are used, then general ovarian cancer detection is possible, but SCCOHT specifically cannot be detected due to lack of specific biomarkers and genetic understanding
Solution Approach 1:
The patent performs preliminary genetic analysis by sequencing the SMARCA4 gene and analyzing SWI/SNF complex composition before clinical diagnosis. This preliminary action identifies inactivating mutations and complex disruptions that serve as specific biomarkers for SCCOHT, enabling early and accurate detection before the disease progresses to advanced stages where conventional methods fail.
Solution Approach 2:
The patent introduces genetic markers (SMARCA4 mutations) and molecular analysis methods as intermediaries between the disease state and clinical diagnosis. These intermediaries provide specific biological information that bridges the gap between conventional screening and accurate SCCOHT detection, allowing physicians to identify the disease with high precision.
2Reliability
If SCCOHT is diagnosed at advanced stage (conventional approach), then diagnosis is possible, but treatment response is poor and mortality rate exceeds 75%
Solution Approach 1:
The patent enables preliminary identification of SCCOHT through genetic testing for SMARCA4 inactivating mutations and SWI/SNF complex analysis. This preliminary action allows diagnosis at early stages rather than waiting for advanced disease presentation, providing sufficient time for effective treatment intervention before the 75% mortality threshold is reached.
3Ease of manufacture
If chemotherapy is administered to SCCOHT patients (standard treatment), then treatment is provided, but response rate is negligible due to chemotherapy resistance
Solution Approach 1:
The patent identifies specific genetic parameters (SMARCA4 mutation status, SWI/SNF complex composition) that define SCCOHT and its resistance to conventional chemotherapy. By changing the treatment approach based on these genetic parameters—from standard chemotherapy to targeted therapies against the SWI/SNF complex dysfunction—the patent overcomes treatment resistance and improves effectiveness.
Solution Approach 2:
The patent introduces genetic characterization data as an intermediary between the disease state and treatment selection. This intermediary information reveals the molecular mechanism of chemotherapy resistance and guides the selection of alternative targeted therapies, transforming treatment from a trial-and-error approach to a precision medicine approach.
4Measurement precision
If genetic analysis of SWI/SNF complex is performed, then accurate SCCOHT identification is achieved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent extracts and focuses analysis on specific critical elements: the SMARCA4 gene sequence and key SWI/SNF complex subunits. By taking out only these essential components for analysis rather than performing comprehensive genomic sequencing, the patent achieves high diagnostic precision while reducing methodological complexity and cost.
Data Source
AI summary
The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The invention also relates to a method of treating a mammalian subject having SCCOHT or a predisposition for SCCOHT.